Menu
FDA DECISION ·
Pebrilzo
pertuzumab-qcay · Biocon Biologics
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
A Perjeta biosimilar for specified HER2-positive breast cancer combinations: first-line metastatic use with trastuzumab and docetaxel; neoadjuvant use with trastuzumab and chemotherapy for locally advanced, inflammatory or early disease; and adjuvant use with trastuzumab and chemotherapy for early disease at high recurrence risk. The label sets the detailed eligibility limits.
SUPPORTING DATA
Evidence behind the decision
- Study
- FDA approved BLA 761501 under section 351(k), referencing US-licensed Perjeta.
- Key result
- The regulatory finding is biosimilarity for the labeled conditions of use.
- Safety to report
- The label includes boxed warnings for left ventricular dysfunction and embryo-fetal toxicity.
- Evidence limits
- This is not evidence of superior efficacy, a new indication for pertuzumab, or a demonstrated commercial launch.
LAMPGEN ANALYSIS
Why it matters
Biosimilarity expands product options for established regimens. The approval letter does not grant interchangeability.
What research teams should watch
For research sites, reconcile exact product identity, protocol-permitted substitutions, pharmacy accountability, infusion procedures and cardiac assessments before any switch.
PRIMARY RECORDS